BioSpace News Archive

Drug Development

FDA Orders Incyte to Wait for Review of Vitiligo Treatment

Incyte Corporation reported that the FDA has pushed back the review of the company’s supplemental New Drug Application (sNDA) for Opzelura (ruxolitinib cream) for vitiligo.

March 14, 2022
·
3 min read
·
Mark Terry
Business

AstraZeneca’s Lynparza Bags Another Breast Cancer Indication

The U.S. FDA has approved Lynparza for the adjuvant treatment of patients diagnosed with germline BRCA-mutated HER2-negative high-risk early breast cancer.

March 14, 2022
·
3 min read
·
Vanessa Doctor, RN
Drug Development

Biogen Announces New Spinraza Data Ahead of Presentation

In the latest results shared by the company, treatment with nusinersen for a median of 4.9 years helped participants maintain and make progressive gains in motor function.

March 14, 2022
·
3 min read
·
Hayley Shasteen
Business

Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors

Rocket Pharmaceuticals, Inc. today announces the appointment of Fady Malik, M.D., Ph.D., to its Board of Directors.

March 14, 2022
·
6 min read
Drug Development

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial

Nektar Therapeutics (NASDAQ:NKTR) will hold an analyst and investor conference call with Nektar management today, Monday, March 14, 2022, at 5:00 a.m. Pacific Standard Time (PST), following this morning’s update from Bristol-Myers Squibb and Nektar on the pivotal Phase 3 PIVOT IO-001 study.

March 14, 2022
·
1 min read
Business

Akumin to Host Year-end 2021 Financial Results Call on March 17, 2022

Akumin Inc. will host a conference call at 8:00 a.m. Eastern Time , March 17, 2022, to discuss its year-end 2021 financial results.

March 14, 2022
·
3 min read
FDA

Fresenius Kabi Receives U.S. Food and Drug Administration 510(k) Clearance for Wireless Agilia® Connect Infusion System with Vigilant® Software Suite-Vigilant® Master Med Technology

Fresenius Kabi Receives U.S. Food and Drug Administration 510(k) Clearance for Wireless Agilia ® Connect Infusion System with Vigilant ® Software Suite-Vigilant ® Master Med Technology.

March 14, 2022
·
3 min read
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

Can-Fite BioPharma Ltd today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (PTO) for its invention titled “Method for Treating Fibrotic Liver Tissue Using CL-IB MECA”.

March 14, 2022
·
7 min read
Drug Development

Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy

Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink ™ Therapy.

March 14, 2022
·
4 min read
Biotech Bay

Potrero Medical CEO Joe Urban to Present at 2022 LSI Emerging MedTech Summit

Potrero Medical, announced today that Joe Urban , Potrero’s Chief Executive Officer, has been invited to present at the 2022 Life Science Intelligence (LSI) Emerging MedTech Summit on Thursday, March 17.

March 14, 2022
·
1 min read